** Cancer therapy developer Coeptis Therapeutics' COEP.O shares rise 2.3% to $11.15
** Co says it has licensed worldwide development and commercialization rights to cell therapy platform GEAR
** As part of the agreement with VyGen-Bio, Coeptis has formed a new majority-owned subsidiary, GEAR Therapeutics, to advance applications of the technology
** GEAR (Gene Edited Antibody Resistant) cell therapy platform modifies immune cells to effectively target and destroy cancer cells without being neutralized by antibodies taken during treatment
** Up to last close, COEP has risen 13.5% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.